About DDX41
No gene-level summary was recorded for this case.
No variant summary was recorded for this case.
Five-step scale from benign to pathogenic. Select a step to read what it means.
Not classified yet.Select a step to read what it means.
Gene-level background from the recorded interpretation.
Words with a dotted underline have a short definition. Hover or tap them.No gene-level summary was recorded for this case.
The recorded framework is ClinGen DDX41 VCEP v1.0.0. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.
The applied criteria and their strengths are shown as assessed under the stated framework.
No pathogenic criterion marked as applied in the recorded assessment.
No benign criterion marked as applied in the recorded assessment.
In progress — classification not generated yet.
Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.
gnomAD v4.1: 20 / 1,614,118 alleles. Recorded AF 1.23907e-05. Recorded homozygote count 0.
This variant is present in gnomAD v2.1 (AF= 1.19311e-05; MAF= 0.00119%, 3/251444 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 2.89084e-05; MAF= 0.00289%, 1/34592 alleles, homozygotes = 0); grpmax FAF= 2.92e-06.
Absent from gnomAD-Canada v1.0.
Recorded SpliceAI maximum delta score: 0.000. Refer to the recorded PP3/BP4 rationale for interpretation.
3 Uncertain significance. ClinVar API review status: criteria provided, multiple submitters, no conflicts.
In progress — evidence not uploaded yet.
This variant has not previously been reported in somatic cancers (COSMIC).
ACMG/AMP criteria under ClinGen DDX41 VCEP v1.0.0, with the data and sources behind each one.
28 criteria with recorded statuses: 0 met · 0 not met · 28 not assessed · 0 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.
No criteria match.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
Every interpreted variant in DDX41, mapped onto the exon structure of NM_016222.2. Select a row to find it on the plot.
| Protein | Location | Classification | Link |
|---|
| Middle Eastern1 / 6,062 | 0.00016 |
| Admixed American1 / 60,030 | 1.7e-05 |
| Remaining individuals1 / 62,502 | 1.6e-05 |
| European (Finnish)1 / 63,932 | 1.6e-05 |
| European (non-Finnish)16 / 1,180,046 | 1.4e-05 |
| Admixed American1 / 34,592 | 2.9e-05 |
| European (non-Finnish)2 / 113,734 | 1.8e-05 |
This variant is present in gnomAD v4.1 (AF= 1.23907e-05; MAF= 0.00124%, 20/1614118 alleles, homozygotes = 0) and has highest observed frequency in the Middle Eastern population (AF= 0.000164962; MAF= 0.01650%, 1/6062 alleles, homozygotes = 0); grpmax FAF= 8.03e-06.
This variant is present in gnomAD v2.1 (AF= 1.19311e-05; MAF= 0.00119%, 3/251444 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 2.89084e-05; MAF= 0.00289%, 1/34592 alleles, homozygotes = 0); grpmax FAF= 2.92e-06.
Absent from gnomAD-Canada v1.0.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
In progress — evidence not uploaded yet.
8 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.
Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.
The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.
This variant is present in gnomAD v4.1 (AF= 1.23907e-05; MAF= 0.00124%, 20/1614118 alleles, homozygotes = 0) and has highest observed frequency in the Middle Eastern population (AF= 0.000164962; MAF= 0.01650%, 1/6062 alleles, homozygotes = 0); grpmax FAF= 8.03e-06.
This variant is present in gnomAD v2.1 (AF= 1.19311e-05; MAF= 0.00119%, 3/251444 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 2.89084e-05; MAF= 0.00289%, 1/34592 alleles, homozygotes = 0); grpmax FAF= 2.92e-06.
Absent from gnomAD-Canada v1.0.
In progress — evidence not uploaded yet.
In progress — evidence not uploaded yet.
In progress — evidence not uploaded yet.
In progress — evidence not uploaded yet.
In progress — evidence not uploaded yet.